NRAS and cutaneous melanoma: This deferred selection for MAP-kinase pathway mutations results in an unexpected heterogeneity in the primary tumors, with BRAF V600E mutation or NRAS Q61 mutations present in some areas of the tumor and absent in others, a finding that is highly unusual for cutaneous melanomas.